ISSN (Print): 2213-476X
ISSN (Online): 2213-4778
Download PDF Flyer
Open Access Funding
Promote Your Article
ISSN (Print): 2213-476X
ISSN (Online): 2213-4778
Aims & Scope
EMBASE, ChemWeb, Google Scholar, J-Gate, CNKI Scholar, Suweco CZ, EBSCO, Ulrich's Periodicals Directory and JournalTOCs.
Submit Abstracts / Manuscripts Online
Animated Abstract Submission
Satish Chandra Tawam Hospital Al Ain UAE
View Full Editorial Board
Order Your Article Before Print
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
Articles submitted between January 01st to August 31st, 2019 will be published as Open Access. Open Access publishing provides greater accessibility to the article. To view some of the Open access articles in the journal, please click here
Quick processing and publication of the submitted papers. The manuscript will be published online within 20 days of final acceptance.
30% discount on the single-issue cost to authors on the purchase of issue(s) in which their article is published.
Multiple issue copies at discounted rates.
I am thankful to Bentham Science Publishers and ACCTRA journal members for being cooperative and supportive during manuscript editing and publishing period. All have indeed been helpful during any queries that occurred.
4 Abstract Ahead of Print are available electronically
12 Articles Ahead of Print are available electronically
The rays of regulations those oversee health care can appear awe-inspiring. Almost every single
facet of this field is supervised by one regulatory body. The latitude and complexity of health care regulation is the
theme of this issue. We expect articles those describes fundamental logic behind the mystifying regulatory network,
recent advancement, suggestions, critiques, case lets as well as strategic interventions of regulatory aspect.
It can be always awe-inspiring to know and understand all the dynamic regulations that spread on the health care
industry. On the top of it, it’s more interesting to identify which regulatory agency is accountable for the
implementation/enforcement of firmnecessities and how it happens as per current move. No one will deny because
Regulation plays a major role in the health care industry and health care industry is mostly driven with health care
insurance coverage. The various regulatory bodies guard the community from a number of health risks. So, these
regulatory agencies not only protect but also control public health neck and neck at every stage. Health care
guidelines, values and standards are always necessary to ensure compliance and to provide safe health care to
each and every individual who accesses the medicines. The health care regulatory agencies in turn monitor
practitioners and facilities, provide information about industry changes, promote safety and ensure legal
compliance and quality services.
We're interested in original research, viewpoints, short communication, case studies projected for regulatory
traits/environment of Pharmaceuticals, Medical devices, Biological and biotechnology products, cosmetics,
veterinary products, Nutraceuticals, Food supplements, Health maintenance organizations (HMOs), Hospital
management firms and Medical and dental practice activities of particular interests dealing with "REGULATORY
TRAITS - RELEVANCE TO CONTEMPORARY HEALTHCARE ENVIRONMENT”.
Major advances in nano-based pharmaceuticals and cosmetics have resulted in breakthrough
developments in improving the health and skin care. The convergence of nanotechnology
with pharmaceuticals and cosmetics is transforming the health and beauty care sector with
several nano-based products in the market or in clinical testing. It is thus mandatory to assess
the regulatory laws for the management of potential risks posed (both human and
environmental) by such nanoproducts. Their toxicity profile needs to be well addressed and
respective regulatory framework to be developed and reinforced by the authorities. In view of
the potentially immense commercial and societal benefits that may come from
nanotechnology, it is likely that nanomaterials, and products and applications containing
them, are being widely investigated, produced and used; but nanotechnology has also brought
new and heightened risks that have not been fully confiscated. Scientists, clinicians and
regulators together have to work on the global harmonization and amend the present
regulatory guidelines to remove the risks posed by the nano-based formulations if any. The
regulatory analysts must review the existing legal mechanisms and determine the adequacy
and efficiency in protecting the safety of consumers. This special issue contains the
regulatory overview of the nanopharmaceuticals and nanocosmetics, and their quality and
safety aspects per se.
No Text Found